From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Risk group
Risk factors
Criteria
Median PFS (months)
Median OS
(months)
Low
0
FGF-2 ≤ 950 pg/dL and
VEGF ≤ 19,000 pg/dL
38
67
Intermediate
1
FGF-2 > 950 pg/dL or
VEGF > 19,000 pg/dL
24
55
High
2
FGF-2 > 950 pg/dL and
15
37